AskBio präsentiert Ergebnisse von Phase-Ib-Studie mit AB-1005 Gentherapie gegen Parkinson nach 18 monatiger Behandlung
Entwicklungskandidat AB-1005 (AAV2-GDNF) von allen 11 Patienten über Zeitraum von 18 Monaten gut vertragen / Keine schwe…
Entwicklungskandidat AB-1005 (AAV2-GDNF) von allen 11 Patienten über Zeitraum von 18 Monaten gut vertragen / Keine schwe…
Entwicklungskandidat Bemdaneprocel zeigt nach 18 Monaten bei allen 12 Patienten in den Kohorten mit niedriger und ho…
As part of this year's BioTech Bootcamp of BioM Biotech Cluster Development GmbH and the life science business incubator…
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in th…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data…
Due to demographic change, age-related brain diseases such as Dementia, Parkinson's disease and Stroke are on the increa…
Partners join forces to improve lives of millions of Parkinson’s patients worldwide with a transformative technology…
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced …
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the…